Soleno Therapeutics EBIT

Soleno Therapeutics (SLNO) currently reports a EBIT of $100M as of March 2026. That compares with $-150M in the prior-year period — up 164.9% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore Soleno Therapeutics's EBIT history and peer comparisons.

Soleno Therapeutics's EBIT increased from $-150M to $100M — a 164.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Soleno Therapeutics's EBIT of $100M is lower than the Healthcare sector average of $99B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Soleno Therapeutics reported $100M in EBIT as of March 2026. That compares with $-150M in the prior-year period — up 164.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $100M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for Soleno Therapeutics, and consider following SLNO for alerts when major investors trade the stock.